Safety Study of CTX001 in Healthy Adults
Part of Blood & lymphatic, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-stage study tests a new experimental drug called CTX001 in healthy volunteers to check if it is safe and well-tolerated. Researchers will also measure how your body processes the drug and how it affects certain blood markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good overall health with no serious medical conditions
- Your BMI must be between 18.0 and 32.0 kg/m² (a measure of height-to-weight ratio)
- Your blood iron levels and related markers must be normal or within an acceptable range
- You must be willing to use effective birth control during the study
- You cannot regularly use cannabis, tobacco, nicotine, or have a history of illicit drugs or alcohol abuse
- You cannot take prescription medications or regular over-the-counter medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how safe APG-5918 is, how the body processes it, and looks for early signs it may help people with certain types of anemia. It may include healthy volunteers and people with anemia, but the study is very selective to protect participants.
This trial tests a new drug called MTX-101 in healthy volunteers to see if it is safe and how the body processes it. It helps determine the right dose before testing in patients with certain conditions.
This trial studies a new drug called XKH001 in healthy volunteers. It is a single-dose study to see how the drug is processed by the body and to check for safety and tolerability.
This trial tests a new drug called LIFE-001 in healthy volunteers to check its safety and how the body handles it. It is for people without significant health issues.
This trial tests a new medication called MTX-439. It includes healthy adults and people with diabetic kidney disease to see if the drug is safe and to learn how the body handles it.
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.